18 The link between metabolic syndrome and nephrolithiasis: a white whale for understanding urinary stone disease
19 Moderation may be the best fad diet for urinary stone disease
20 Mast cell activation syndrome
22 Diagnosis and treatment of benign prostate hyperplasia in Asia
28 Erectile dysfunction: Doctors’ perspectives on patients’ concerns
31 Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
33 Modifying sunitinib schedule in advanced kidney cancer patients: Re ections from the results of the renal EFFECT trial
36 The complexity of sunitinib dosing in renal cell cancer patients
39 Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
41 Milestones for development of tivozanib for kidney cancer therapy
44 Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
46 Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and ef cacy in advanced kidney cancer?
48 Tivozanib: a novel VGFR inhibitor for kidney cancer
51 Enzalutamide (formerly MDV3100) prolongs survival in docetaxelpretreated castration-resistant prostate cancer patients
53 Enzalutamide: the emperor of all anti-androgens
55 Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
57 Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need?
60 Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab
62 Identi cation of biomarkers in pazopanib treated patients with renal cell carcinoma
64 Proposal of “cyclic therapy”, a novel treatment strategy with targeted agents for advanced renal cell carcinoma
68 Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?
72 Immunotherapy in renal cell cancer: the more the merrier?
75 The argument for palliative care in prostate cancer
78 Greenlight laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: evidence from randomized controlled studies
83 Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy
86 What’s new in urological trauma? 2012 update
88 Interpretation of PIVOT ndings
90 Re ning treatment for the men who need it: lessons from the PIVOT trial
93 PIVOT and the challenges of localized prostate cancer care
96 Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
99 Neuromodulation and neurostimulation: overview and future potential
105 Gastric bypass surgery patients warrant special attention for preventing urinary stones
106 Ureteral stents are part of an ever-expanding technology horizon
107 Injection therapy for Peyronie’s disease: pearls of wisdom
111 Looking beyond the guidelines for perioperative antibiotics in nephrolithiasis
112 Should perioperative anticoagulation be an integral part of the priapism shunting procedure?
117 Clinical challenges in tissue-engineered urethral reconstruction
121 Predicting the future of urodynamics
123 Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing
126 New prognostic models in metastatic renal cancer
128 Is there a sexual life after treatment of cancer?
Special Case Analysis
131 Commentary on refractory ischemic priapism
136 Commentary on high ow, non-ischemic, priapism
140 Commentary on the myths of Peyronie’s disease
146 Randall plaque versus renal stone?
Cost Effective Management
151 The days of cost effective management for nephrolithiasis are already upon us
152 Balancing the utility of new technology against cost in urinary stone disease